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Objective: Mice homozygous for targeted deletion of the gene encoding fibroblast growth
factor receptor 3 (FGFR3−/−) develop kyphoscoliosis by 2 months of age. The first objec-
tive of this study was to use high resolution X-ray to characterize curve progression in vivo
and micro CT to quantify spine architecture ex vivo in FGFR3−/− mice. The second objec-
tive was to determine if slow release of the bone anabolic peptide parathyroid hormone
related protein (PTHrP-1-34) from a pellet placed adjacent to the thoracic spine could inhibit
progressive kyphoscoliosis.
Materials and methods: Pellets loaded with placebo or PTHrP-1-34 were implanted adja-
cent to the thoracic spine of 1-month-old FGFR3−/− mice obtained from in house breeding.
X rays were captured at monthly intervals up to 4 months to quantify curve progression
using the Cobb method. High resolution post-mortem scans of FGFR3−/− and FGFR3+/+
spines, from C5/6 to L4/5, were captured to evaluate the 3D structure, rotation, and
micro-architecture of the affected vertebrae. Un-decalcified and decalcified histology were
performed on the apical and adjacent vertebrae of FGFR3−/− spines, and the corresponding
vertebrae from FGFR3+/+ spines.
Results:The mean Cobb angle was significantly greater at all ages in FGFR3−/− mice com-
pared with wild type mice and appeared to stabilize around skeletal maturity at 4 months.
3D reconstructions of the thoracic spine of 4-month-old FGFR3−/−mice treated with PTHrP-
1-34 revealed correction of left/right asymmetry, vertebral rotation, and lateral displacement
compared with mice treated with placebo. Histologic analysis of the apical vertebrae con-
firmed correction of the asymmetry in PTHrP-1-34 treated mice, in the absence of any
change in bone volume, and a significant reduction in the wedging of intervertebral disks
(IVD) seen in placebo treated mice.
Conclusion: Local treatment of the thoracic spine of juvenile FGFR3−/− mice with a bone
anabolic agent inhibited progression of scoliosis, but with little impact on kyphosis. The
significant improvement in IVD integrity suggests PTHrP-1-34 might also be considered as
a therapeutic agent for degenerative disk disorders.
Keywords: progressive kyphoscoliosis, fibroblast growth factor receptor 3 deficiency, parathyroid hormone-related
peptide treatment, radiography, micro-computed tomography, histology
INTRODUCTION
Scoliosis is a pathological condition characterized by lateral curva-
ture of the spine in the coronal (front–back) plane, whereas kypho-
sis is excessive angulation of the spine in the sagittal (sideways)
plane. Scoliotic disorders are generally classified into congenital
forms, such as those arising from fundamental flaws in skeletal
patterning in the embryo, those resulting from neuromuscular
disorders, and the vast majority of cases that are of undetermined
origin (1, 2). The presence of scoliosis before the age of 5 years
is defined as early onset scoliosis (EOS) and leads to severe, three
dimensional deformation of the spine in ~1/2500 children. The
deformity impedes normal lung development and contributes to
the primary morbidity associated with the condition (3). While
the effects of EOS treatment on morbidity are not fully under-
stood, it has been established that early fusion of the spine to
prevent progression of the curve can be further detrimental to
pulmonary health (4). Alternative growth-sparing techniques that
allow ongoing development of the spine and thoracic cage are
therefore encouraged. These techniques rely on bracing, serial
casting, and in refractory cases the use of “growing rods” for
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bio-mechanical correction and inhibition of curve progression.
Growing rods are surgical implants placed in the posterior spine
to guide longitudinal growth and alignment of the spine. The
treatment is fraught with serious complications associated with
high financial and psychosocial burden that include significant
pain, loss of spinal mobility, and junctional deformity in adjacent
vertebrae.
The vast majority of pre-clinical animal models that have been
developed to study scoliosis have relied on post-natal interventions
including damage to the central nervous system and biomechan-
ical constraints on spine growth (5). However, a genetic basis
for some forms of scoliosis is suggested by studies of mice from
dams subjected to teratogens like N -ethyl-N -nitrosourea (6, 7)
and carbon monoxide (8), as well as those carrying spontaneous
or targeted mutations in genes known to impact the develop-
ment of neuromuscular and skeletal tissues. For example, mice
homozygous for targeted disruption of the gene encoding fibrob-
last growth factor receptor 3 (FGFR3 OMIM 134934) exhibit EOS
in association with overgrowth of the axial and appendicular skele-
ton (9, 10). Skeletally mature FGFR3−/− mice have also been
characterized with reduced cortical bone thickness, defective tra-
becular bone mineralization, premature joint degeneration, and
early arthritis (11, 12).
Parathyroid hormone related protein (PTHrP) was first cloned
from malignant tumors removed from patients with a para-
neoplastic syndrome known as humoral hypercalcemia of malig-
nancy (13, 14). When released by the tumor into the circulation,
the protein, which shares sequence homology with parathyroid
hormone (PTH), activates PTH receptors to promote release of
calcium from bone and its retention in the kidney (15, 16). Bio-
chemical and physiological analyses determined that PTHrP-1-34
is homologous with PTH-1-34 and binds to the PTH cell surface
receptor on target cells, including chondrocytes and osteoblasts
(17, 18). A central role for PTHrP in skeletal development was
later demonstrated when PTHrP-null mice died at birth with lethal
skeletal dysplasia (19) and their heterozygote littermates developed
osteopenia as young adults (20). Unlike the catabolic effect medi-
ated by high levels of circulating PTH/PTHrP, the 1–34 peptide
mediates anabolic activity on cells when released into the bone
micro-environment (21).
FGFR3−/− mice have been characterized with osteopenia (11),
which has been established as a risk factor for curve progression
in patients with scoliosis (22). The objective of this study was to
use micro CT to quantify progressive kyphoscoliosis in FGFR3−/−
mice and to determine if treatment with PTHrP-1-34 could inhibit
curve progression. Slow release of the bone anabolic peptide adja-
cent to the thoracic spine inhibited progression of scoliosis but
had little impact on kyphosis or bone volume. The micro CT data
was supported by histological analyses of the spine.
MATERIALS AND METHODS
IN VIVO RADIOLOGIC IMAGING OF MOUSE SPINE
All in vivo procedures were conducted as outlined in a protocol
approved by McGill Facility Animal Care Committee in com-
pliance with the Canadian Council on Animal Care. Male and
female FGFR3+/+ and FGFR3−/− mice used for this study were
obtained through in house breeding from a colony maintained
for 20 generations on a C3H background. The mice were lightly
anesthetized at the indicated times and carefully positioned to
capture coronal and sagittal plane radiographs (Kubtek XPERT
80, Milford, CT, USA). Gingko CADx 2.4.1 software (Valladolid,
Spain) was used to assess gross anatomical measurements and to
measure the magnitude of the largest scoliotic and thoraco-lumbar
kyphotic curves, according to the Cobb method (23).
TREATMENT WITH SYNTHETIC PTHrP-1-34
Slow-release pellets measuring 3 mm in diameter and designed
to release 1.0 mg PTHrP-1-34 (N = 16) or placebo (N = 18) over
60 days were manufactured by Innovative Research of America
(Sarasota, FL, USA). The pellets were implanted in 4-week-old
FGFR3−/− mice under general anesthesia on the left side of the
spine adjacent to the thoraco-lumbar junction, then maintained
for 12 weeks with free access to food and water. Radiographic imag-
ing on anesthetized mice was performed at monthly intervals as
described above, and the mice were euthanized by injection of an
overdose of anesthetic at 16 weeks of age. Spines were extracted
by cutting through the neck and separating the thoracic and lum-
bar vertebrae from the ribs and pelvis, cleaned of soft tissue, and
fixed in 4% paraformaldehyde for 24 h. The fixed spines were then
washed in several changes of sterile PBS and stored in PBS at 4°C
until the time of micro CT analysis (24).
POST-MORTEMMICRO CT ANALYSES
High resolution scans of the spine of FGFR3−/− (N = 16 treated
with PTHrP-1-34; N = 18 treated with placebo) and FGFR3+/+
(N = 5) mice from C5/6 to L4/5 were captured to evaluate the 3D
structure, as well as the rotation of the vertebrae in the curve of
FGFR3−/−mice. Scans were captured at 8µm spatial resolution on
a Skyscan 1172 micro-computed tomograph (micro CT, Bruker,
Kontich, Belgium) equipped with a 0.5 mm aluminum filter at a
voltage of 55 kV, a current of 180µA, and a power source of 10 W.
The rotation step size used for acquiring images was 0.4°. NRecon
and CTVol software was used for transverse 2D cross-sectional
reconstructions and 3D reconstruction of sub-sets of images.
CTAn software supplied with the instrument was used for
quantitative analysis of bone mass and architecture, apical verte-
bra axial rotation, and geometric properties. Axial rotation of the
apical vertebra, as defined by the Scoliosis Research Society (25),
was quantified by loading the dataset in Dataviewer and rotating
the images to align the anterior and posterior borders of the L5
vertebral body in the horizontal plane. The fifth lumbar vertebra
then served as the reference point for measuring the angle of rota-
tion. The properly aligned images were saved as a new dataset and
loaded into CTAn to locate the apical vertebra, which is the most
rotated vertebra (26). The angle of rotation was measured from
the horizontal plane to the straight line from the mid-points of
the anterior to posterior surfaces of the apical vertebra.
The L5 vertebral body lays outside of the scoliotic curve in
all animals and was therefore used as a reference point to assess
bone volume/total volume (BV/TV), which is the primary mea-
sure of bone quality. The transverse view image datasets for L5
from FGFR3−/− and FGFR3+/+ mice were used to isolate trabec-
ular bone as the ROI by excluding the vertebral arch and cortical
bone. Trabecular bone was then segmented into left, middle, and
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right portions to calculate BV/TV of the outer (left and right) seg-
ments independently. A 3D volume of interest (VOI) that included
only the middle 50% of the vertebral body was selected to avoid
the endplate region. BV/TV values for bone within the VOI was
obtained using CTAn. BV/TV for the apical vertebra in FGFR3−/−
mice was calculated in the same manner.
The concave/convex geometry of the apical vertebra in
FGFR3−/− spines was evaluated using cross-sectional images iso-
lated in CTAn and loaded for 3D viewing in Dataviewer. The
mid-vertebral body coronal image was saved and the lengths of the
concave and convex sides measured from the superior to inferior
endplates using CTAn to quantify lateral asymmetry. The same
measurements were made on the apical-equivalent vertebra in
FGFR3+/+ mice as a control.
HISTOLOGICAL ANALYSES
After micro CT analyses, the apical and adjacent vertebrae of
FGFR3−/− (N = 16 treated with PTHrP-1-34; N = 18 treated
with placebo) spines, and the corresponding vertebrae from the
FGFR3+/+ (N = 5) spines, were carefully dissected free from
the remaining vertebrae, fixed in 4% paraformaldehyde for 24 h,
and embedded at low temperature in poly-methyl-methacrylate
(PMMA) as described previously (24). Five micron sections were
cut from the polymerized blocks on a Leica microtome and stained
with von Kossa/Toluidine blue to distinguish mineralized from soft
tissue, with Safranin O to delineate intervertebral disks (IVDs)
and vertebral end plates, and for alkaline phosphatase (ALP)
and tartrate-resistant acid phosphatase (TRAP) in anabolic and
catabolic cells, respectively. Image J software was used to quantify
ALP and TRAP activity on the concave vs convex aspects.
STATISTICAL ANALYSES
A Mann–Whitney U test for unpaired samples in the IBM SPSS
Statistics (Armonk, NJ, USA) package was used to compare differ-
ences in the degrees of scoliosis, kyphosis, axial rotation of apical
vertebrae, and concave vs convex height of the apical vertebral
body. A one way analysis of variance (ANOVA) with post hoc
Tukey’s test was used for comparison of BV/TV. Differences were
considered significant at p< 0.05.
RESULTS
Kyphoscoliosis was previously noted in juvenile FGFR3−/− mice
on a mixed C57Bl6 background but was never characterized (9,
10). The genotype was later transferred onto a C3H background
to improve longevity and enable phenotyping of adult mice (11,
12). Table 1 shows the Cobb angle of thoracic vertebrae measured
in large cohorts of FGFR3+/+ and FGFR3−/− mice, aged between
1 and 6 months, that were euthanized in our laboratory. Intra-
group variations in spine curvature are remarkably small amongst
FGFR3+/+ mice compared with the large variations in groups of
FGFR3−/− mice. Beyond 1 month, the mean Cobb angle is sig-
nificantly greater at all ages in mutant FGFR3−/− mice compared
with FGFR3+/+ wild type mice (33.30± 19.55° vs 5.06± 3.39° at
4 months, p< 0.01) and appears to stabilize around 4 months of
age when the animals reach skeletal maturity.
PROGRESSION OF SCOLIOSIS IN FGFR3−/− MICE
To analyze scoliosis, cohorts of FGFR3+/+ and FGFR3−/− mice
were anesthetized at monthly intervals from 1 to 4 months to cap-
ture high resolution coronal and sagittal X-rays of the spine. Serial
radiographs of representative mice, shown in Figure 1, reveal an
established sigmoid curve at 2 months in the FGFR3−/− mouse
compared with the FGFR3+/+, which increases in severity to
4 months when the mice were euthanized. As shown in Figure 2,
continuous release of PTHrP-1-34 from pellets implanted adja-
cent to the thoracic spine at 1 month of age inhibited progression
of scoliosis but did not alter the development of kyphosis in
FGFR3−/− mice.
MICRO CT ANALYSIS OF THE SCOLIOTIC CURVE IN FGFR3−/− MICE
In keeping with the clinical assessment of scoliosis, we evaluated
the lateral displacement of vertebrae along the horizontal plane
and their rotation in the axial plane. Using the L5 vertebra as
a reference point outside of the curve, the vertebra with maxi-
mal lateral displacement and rotation was identified as the apical
Table 1 | Development of scoliosis, measured by Cobb angle, in growing FGFR3−/− mice.
Genotype Age (months) N Minimum (degrees) Maximum (degrees) Mean±SD (degrees)
FGFR3+/+ 1 9 0.37 14.41 6.2±4.64
FGFR3−/− 1 12 1.15 46.60 11.01±11.95
FGFR3+/+ 2 25 1.43 15.04 4.86±3.74
FGFR3−/− 2 40 0.91 62.46 15.79±12.82*
FGFR3+/+ 3 36 0.65 14.98 4.91±2.92
FGFR3−/− 3 57 2.71 105.47 31.60±21.33*
FGFR3+/+ 4 38 0.95 14.76 5.06±3.39
FGFR3−/− 4 43 5.51 101.28 33.30±19.55*
FGFR3+/+ 5 16 0.93 13.19 5.23±3.31
FGFR3−/− 5 20 6.98 80.18 32.45±19.29*
FGFR3+/+ 6 17 0.93 11.91 4.93±3.55
FGFR3−/− 6 21 15.29 77.34 40.92±17.14*
Significantly different from FGFR3+/+ mice *p<0.01.
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FIGURE 1 | Radiographic evidence of progressive scoliosis in
FGFR3−/− mice: high resolution radiographs were taken of
anesthetized mice at monthly intervals up to 4 months of age. Serial
radiographs of representative mice shows no evidence of spine
curvature in the FGFR3+/+ animal (upper) at any time point. The FGFR3−/−
animal (lower) shows little evidence of deformity at 1 month, compared
with the sigmoid curve that is evident at 2 months, and increases in
severity to 4 months.
FIGURE 2 |Treatment with PTHrP-1-34 inhibits scoliosis but not kyphosis
in FGFR3−/− mice: At 1 month of age, FGFR3-null mice were randomly
assigned to groups to receive pellets loaded with placebo (upper,
N =18) or with PTHrP-1-34 (lower, N =16), which were placed adjacent
to the thoracic spine through a small skin incision. Coronal (left) and
sagittal (right) radiographs were taken at the time of pellet implantation and at
monthly intervals until 4 months, when the mice were euthanized and the
spines removed for micro CT analyses (graph). Continuous, local treatment of
the growing spine with PTHrP-1-34 in FGFR3−/− mice inhibited progression of
scoliosis but had little impact on kyphosis *p<0.03
vertebra. The 2D cross-sectional micro CT images of a representa-
tive FGFR3−/− spine shown in Figure 3 reveal significant rotation
of T8 through T12 in the presence of a relatively small lateral dis-
placement of the spine. 3D reconstructions of the lower thoracic
spine of representative FGFR3−/− mice show that treatment with
placebo (Figure 3B) does not correct the lateral curvature or axial
rotation, whereas both are improved in mice treated with pellets
that release PTHrP-1-34.
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FIGURE 3 | PTHrP-1-34 inhibits rotation of apical vertebra in
FGFR3−/− mice: An X-ray of the intact spine of an FGFR3−/− mouse
captured by micro CT (A), is shown adjacent to the mid-region 2D
CT images of the identified vertebrae (B). The L5 image was aligned in
the horizontal axis (dotted line) as a reference point to measure the
degree of axial rotation (arrows) on T8, T10, and T12. 3D reconstruction of
the lower thoracic spine of FGFR3+/+ (C) and FGFR3−/− (D,E) mice
revealed an overall reduction in axial rotation of the vertebrae in
FGFR3−/− mice treated with PTHrP-1-34 (C, N =16) compared with mice
treated with placebo [(B), N =18]. Quantitative analysis of axial rotation
of the apical vertebra in placebo (white) and PTHrP-1-34 (gray) treated
mice is shown in the bar graph (F).
TREATMENT WITH PTHrP-1-34 HAS MINIMAL IMPACT ON
VERTEBRAL BONE
To further characterize the defects in the spine of FGFR3−/−
mice, the composition and architecture of the apical vertebrae
were analysed using quantitative micro CT. The 3D reconstruc-
tions shown in the coronal plane (Figures 4A–C) in Figure 4
show the reduction in trabecular bone that characterizes the
skeletons of FGFR3−/− mice. The coronal images (Figures 4D–
F) confirm the left/right symmetry in the FGFR3+/+ vertebra
and asymmetry and rotation in the FGFR3−/− placebo treated
mouse (Figure 4E), which are partially corrected in the PTHrP-
1-34 treated animal (Figure 4F). Quantitative analysis of the L5
vertebrae showed a significant reduction in BV/TV in FGFR3−/−
mice. Independent analysis of the concave and convex sides of the
apical vertebrae showed BV/TV in the concave side to be com-
parable to that in FGFR3+/+ vertebrae, while that in the convex
side remained the same as the L5 reference. Table 2 shows sig-
nificant differences in the quantitative micro CT parameters for
the concave and convex sides of the apical vertebrae in FGFR3−/−
spines compared with no difference in FGFR3+/+ spines. Between-
group comparisons confirmed previous observations of an overall
increase in the length of vertebrae in FGFR3−/− mice, but also a
significant reduction of height on the concave side of IVDs, mea-
sured indirectly as the distance between the endplates of adjacent
vertebrae.
TREATMENT WITH PTHrP-1-34 MAINTAINS IVD INTEGRITY
Qualitative differences in the vertebral bodies and IVDs in
response to placebo and PTHrP-1-34 treatment are shown in
Figure 5. Low magnification images of Safranin O-stained spines
(Figures 5A,B) clearly demonstrated the improvement in lin-
earity in PTHrP-1-34 treated mice. Higher magnification images
revealed wedging in association with deterioration of the muco-
protein in the nucleolus pulposus and apparent disorganization of
the annulus fibrosus in placebo treated (Figure 5C) compared with
PTHrP-1-34 treated (Figure 5G) IVDs. Staining of un-decalcified
bones with von Kossa/Toluidine blue (Figures 5D,H) showed
more bone on the concave than convex side of the apical verte-
bra in both treatment groups. However, as shown in the Safranin
O-stained sections there was a clear improvement in morphol-
ogy in PTHrp-1-34 compared with placebo treated mice (arrows;
Figure 5D vs Figure 5H). Quantification of ALP (Figures 5E,I)
and TRAP (Figures 5F,J) staining in the vertebral end plates also
showed no significant differences between placebo and PTHrP-1-
34 treated animals (ALP 8.0± 7.7 vs 17.3± 10.9; TRAP 10.9± 4.4
vs 15.6± 3.5).
DISCUSSION
The goal of this study was to analyze the progression of kypho-
scoliosis in osteopenic FGFR3−/− mice and to determine if local-
ized treatment with a peptide known to promote bone formation
in vivo could inhibit progression of the deformity. Micro CT and
histological analyses showed that sustained release of PTHrP 1-34
from pellets placed adjacent to the thoracic spine inhibited pro-
gression of the scoliotic curve, but had little impact on kyphosis
or osteopenia.
A technique for quantification of the lateral displacement of the
spine in patients with scoliosis was developed by the orthopedic
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FIGURE 4 | PTHrP-1-34 treatment does not alter BV/TV in apical
vertebra of FGFR3−/− mice: 3D reconstruction of the apical vertebra
from treated FGFR3−/− mice were compared with the corresponding
vertebra from FGFR3+/+ mice. Coronal 3D images (A–C) show reduced
trabecular bone in the FGFR3−/− vertebrae (B,C) regardless of treatment,
compared with the FGFR3+/+ vertebra (A). 3D reconstructions (D–F) show
wedging of the apical vertebra in placebo treated [(E), N=18] mice
compared with that of PTHrP-1-34 treated mice [(F), N =16] or FGFR3+/+
control [(D), N =5]. Trabecular bone was segmented into three regions
[(G) dotted lines] to quantify bone volume as a percentage of tissue
volume (BV/TV). The middle segment was excluded and the outer
segments were analyzed separately to capture the Concave and Convex
sides of the apical vertebrae. Quantitative analysis confirmed a significant
reduction in BV/TV in the L5 reference vertebra of FGFR3−/− mice treated
with placebo (white bar) and PTHrP-1-34 (gray bar) compared with
FGFR3+/+ (black bar) mice. Concave/convex asymmetry (E) was reflected
in a lower BV/TV on the convex compared with concave aspect of the
apical vertebrae, with no significant impact of PTHrP treatment.
*p<0.05 compared with FGFR3+/+; ε p<0.05 compared with Concave
aspect.
Table 2 | Quantitative micro CT analysis of apical vertebrae in the primary curve.
Parameter Units FGFR3+/+ FGFR3+/+ FGFR3−/− FGFR3−/−
concave convex concave convex
N =17 N =17 N =17 N =17
BV/TV % 15.22±3.41 15.32±3.00# 17.11±5.02 11.73±4.74**
Tr.Th. mm 0.06±0.01 0.06±0.01 0.06±0.01 0.06±0.01
Tr.N. mm−1 2.44±0.47 2.46±0.34# 2.71±0.68 1.99±0.70**
Connectivity mm−3 37.12±21.98 38.24±23.68 48.82±17.01 32.53±19.59**
Height mm 2.06±0.75## 2.06±0.76## 2.34±0.49 2.47±0.53
IVD width mm 0.29±0.08# 0.29±0.08 0.23±0.08 0.26±0.07*
Significantly different from FGFR3−/−; #p<0.05; ##,**p<0.01.
Significantly different from contralateral side; *p<0.05; **p<0.01.
surgeon John Cobb in the late 1940s and remains as the preferred
technique for assessment of curve severity (23). Measurement
of the Cobb angle on serial antero–posterior radiographs of the
spines of growing mice revealed 62 of 63 FGFR3−/− mice and
no FGFR3+/+ mice met the criteria for scoliosis at the time of
euthanasia between 4 and 6 months of age. Rapid progression of
the curve coincided with rapid body growth up to 4 months, when
the mice reached skeletal maturity, and slowed thereafter.
The phenotype of FGFR3−/− mice overlaps with that of indi-
viduals carrying a missense mutation in the tyrosine kinase
domain of FGFR3 that results in camptodactyly, tall stature, and
hearing loss or CATSHL syndrome (OMIM 610474) (27, 28). Phe-
notypes that include scoliosis are also seen in humans and mice
with mutations in genes encoding proteins involved in the down-
stream signaling pathways of cell surface receptors like FGFR3.
One example is von Recklinghausen Disease or Neurofibromatosis
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FIGURE 5 | PTHrP-1-34 treatment inhibits IVD compression in FGFR3−/−
mice: After micro CT analyzes representative spines from FGFR3−/− mice
were de-calcified, embedded in paraffin, and thin sections stained with
Safranin O [(A–C,G) orange] to delineate IVD and cartilage endplates of
the vertebra or for ALP (E,I) orTRAP (F,J) enzyme activity. Some spines
were embedded un-decalcified in plastic for von Kossa/Toluidine blue staining
of bone (D,H). Histologic analysis of the thoracic spine (A,B) confirmed the
positive influence of PTHrP-1-34 treatment in reducing curvature and axial
rotation shown in the radiology. Higher magnification images of apical
vertebrae revealed deterioration and asymmetric compression of the IVD in
placebo treated FGFR3−/− mice [asterix (C)], which was not apparent in
PTHrP-1-34 treated mice. Von Kossa stained sections revealed a concentration
of bone on the concave vs convex side of FGFR3−/− vertebrae [(D,H) black]
and confirmed the correction of the IVD phenotype with PTHrP-1-34
treatment [(D,H) arrows]. There were no clear differences in the ALP and
TRAP activity in adjacent vertebrae [(E) vs (I) and (F) vs (J)].
Type 1. This autosomal dominant disorder arises from disrup-
tion of the neurofibromin gene (OMIM 613113), which encodes a
large cytoplasmic protein that regulates several intracellular signal-
ing molecules (29). Another example is disruption of the protein
tyrosine phosphatase non-receptor type 11 gene (PTPN11 OMIM
176876) encoding the Src-homology 2 phosphatase downstream
of FGF receptors (30).
In contrast to the relatively rare incidence of CATSHL syn-
drome caused by FGFR3 inactivation, activating mutations in
FGFR3 that result in achondroplasia (31) and hypochondropla-
sia (32) occur at an estimated frequency between 1/15,000 and
1/40,000 live births. Affected individuals exhibit kyphoscoliosis in
association with short-limbed dwarfism in the growing post-natal
skeleton (33). Others less fortunate carry activating mutations that
results in a peri-natal lethal form of short-limbed dwarfism called
Thanatophoric dysplasia (TD) (34). Like the FGFR3−/− mice,
these babies show little evidence of kyphoscoliosis at birth. The
sporadic mutations that result in TD are distributed throughout
the extracellular and intracellular components of FGFR3, which
exemplifies the heterogenous nature of the disorder. Targeted
mutations in the mouse FGFR3 gene have replicated the phenotype
of some human skeletal dysplasias to some extent but have failed
to clarify the pathogenesis of scoliotic curve progression (35–37).
The consistency with which FGFR3−/−mice develop kyphoscolio-
sis during post-natal growth identify them as a valuable resource to
further explore its pathogenesis and potential therapeutic options.
In comparison with placebo, treatment of FGFR3−/− mice
with PTHrP 1-34 appeared to reduce spine curvature suggest-
ing its activity might be complementary to that of FGF signaling
through FGFR3 in skeletally mature mice. Previous work showed
compound mutant FGFR3−/−/PTHrP−/−mice die in the perinatal
period with skeletal abnormalities less severe than those seen in the
single mutant PTHrP−/− littermates (38). This study concluded
that PTHrP regulated the pool of growth plate chondrocytes,
while signaling through FGFR3 played a more pronounced role
in turnover of cartilage to bone at the chondro–osseous junction.
Additional studies in skeletally mature FGFR3−/− mice revealed
osteopenia arising from defective osteoblast mineralization (11).
Taken together this work supports the hypothesis that comple-
mentary signaling through PTH1R and FGFR3 pathways regulate
cartilage and bone growth and metabolism by targeting different
cell populations.
Recombinant PTH 1-34 is the only anabolic medication for
the treatment of osteoporosis that has been approved for use
in humans (39), although its mechanism of action remains
poorly defined. The results of decades of intense investigation
has determined that pre-osteoblasts in bone marrow, mature
osteoblasts adjacent to the bone surface, and osteocytes embed-
ded in bone matrix all respond to intermittent stimulation with
amino-terminal fragments of PTH and PTHrP (17, 40, 41). In
the current study, PTHrP-1-34 treatment resulted in blunting of
the coronal plane scoliosis in FGFR3−/− mice as evidenced by a
reduction in the discrepancy between concave and convex lengths
of the apical vertebra. Rotation of the apical vertebra was also less
pronounced in the mice treated with PTHrP-1-34 compared with
those receiving placebo. Although the cause of vertebral rotation
remains un-defined, there is general agreement amongst physi-
cians treating patients with scoliosis that the degree of rotation
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of affected vertebra is increased concomitant with curve severity.
These changes resulted in less severe scoliotic deformity and closer
approximation to the spinal morphology of WT mice, but with lit-
tle change in the kyphotic phenotype. One possible explanation
is that PTHrP-1-34 released from the pellet in the vicinity of the
thoraco-lumbar spine promoted the differentiation of osteogenic
cells to strengthen the vertebrae. This conjecture is supported by
an apparent increase in ALP activity in the vertebral endplates
in our study. Further support comes from a systematic search of
the literature that suggested intermittent treatment of osteoporo-
sis with PTH 1-34 could improve both the speed of healing and
composition of the tissue in cases of spinal fusion (42).
In contrast to the improved symmetry of the apical vertebra
and spine in general in FGFR3−/− mice treated with PTHrP-1-
34, there was little evidence of an improvement in BV/TV in the
apical vertebra compared with the reference L5 vertebra, which
was outside of the curve. The higher BV/TV in the concave com-
pared with convex side of the apical vertebra could have resulted
from an anabolic response to increased biomechanical strain on
the concave side (43). Alternatively, it could result from collapse of
the disorganized trabecular network under increased strain, simi-
lar to the spine compression fractures seen in patients with severe
osteoporosis (44). Given the known biological action of amino
terminal PTH and PTHrP on growth plate and articular chondro-
cytes, the reduction in curvature could also have resulted from the
peptide altering growth and/or metabolism of the cartilaginous
IVDs. This hypothesis was supported by the reduction in wedg-
ing of the IVDs adjacent to the apical vertebra in FGFR3−/− mice
treated with PTHrP-1-34 compared with placebo. However, it has
been proposed in the literature that IVD wedging occurs secondary
to progression of the kyphoscoliotic curve in mice with targeted
disruption of the MECOM gene, which encodes a transcriptional
regulatory protein (45). The lack of apparent impact of PTHrP-1-
34 treatment on BV/TV might also reflect inadequacies in the dose
and/or release kinetics of the peptide from the pellet. Suffice to say
the precise mechanism by which the positive influence of PTHrP-
1-34 in correcting progressive scoliosis in growing FGFR3−/−mice
awaits additional immunochemical analyses in vivo and detailed
analysis of intact spines subjected to controlled loading ex vivo.
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